[Chemotherapy in elderly patients with hematological malignancies].

A half of patients with acute myeloid leukemia and lymphoma are older than 60 years. However, using chronological age for estimating chemotherapy-related risks is unreliable, and patients without comorbidity may be candidates for the standard therapy. For patients who have complex comorbidity or are older than 75 years, a reduced dose of chemotherapy or palliative treatment is appropriate. Molecular targeted therapy may be tolerable for elderly patients.